Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Income from Continuing Operations (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Income from Continuing Operations for 10 consecutive years, with 43746000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 28.93% to 43746000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 230420000.0 through Dec 2025, up 13.64% year-over-year, with the annual reading at 230420000.0 for FY2025, 13.64% up from the prior year.
  • Income from Continuing Operations hit 43746000.0 in Q4 2025 for Rocket Pharmaceuticals, up from 52011000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 33798000.0 in Q2 2021 to a low of 71889000.0 in Q2 2024.
  • Historically, Income from Continuing Operations has averaged 57148150.0 across 5 years, with a median of 61152000.0 in 2023.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 71.22% in 2021 and later rose 28.93% in 2025.
  • Year by year, Income from Continuing Operations stood at 43946000.0 in 2021, then crashed by 55.43% to 68304000.0 in 2022, then grew by 7.86% to 62935000.0 in 2023, then grew by 2.2% to 61550000.0 in 2024, then grew by 28.93% to 43746000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for RCKT at 43746000.0 in Q4 2025, 52011000.0 in Q3 2025, and 71139000.0 in Q2 2025.